Non Hodgkin's Lymphoma Clinical Trial
Official title:
A Phase I Trial of Clofarabine in Combination With High-Dose Etoposide and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation for Patients With High-Risk or Refractory Non-Hodgkin's Lymphoma
Verified date | September 2014 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This is a phase I trial to determine the maximum tolerated dose (MTD) of clofarabine in a combination with high-dose etoposide and cyclophosphamide. This is an initial step in developing a novel myeloablative preparative regimen for autologous hematopoietic stem cell transplantation (ASCT). While this phase I trial will initially develop the regimen in patients with refractory disease, it is expected that it will find its best application in patients with less advanced disease.
Status | Completed |
Enrollment | 18 |
Est. completion date | November 2010 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Documentation of disease. Patients must have one of the following disease types: - Diffuse large cell non-Hodgkin's lymphoma, mediastinal B-cell lymphoma, or peripheral T-cell lymphoma that is: - Primary refractory (achievement less than complete response) - Relapsed and refractory (achievement less than a partial response) to at least a single salvage therapy - Relapsed or primary refractory Follicular lymphoma (FL) with a high FL International Prognostic Index. - Large cell transformation of lymphoma from a more indolent lymphoma (e.g., follicular, marginal zone, etc.) - Mantle cell lymphoma that is: - Primary Refractory (achievement less than complete response) - Relapsed (regardless of chemosensitivity of relapsed disease) 2. Patients who received prior autologous stem cell transplantation are not eligible. 3. Patient age 18-70 years 4. Performance status ECOG 0-1 5. Required baseline laboratory values: - LVEF > 45% corrected - DLCO > 50% of predicted value (corrected for hemoglobin) - Serum creatinine = 2.0 mg/dl or estimated creatinine clearance of =60 ml/min - Bilirubin < 1 x upper limit of normal value. - AST and ALT < 1 x upper limit of normal value. 6. Signed written informed consent. Patient must be capable of understanding the investigational nature of the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent Exclusion Criteria: 1. No active infection. Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection. 2. No HIV disease. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies. 3. Non-pregnant and non-nursing. Treatment under this protocol would expose a fetus to significant risks. Women of childbearing potential should have a negative pregnancy test prior to study entry. Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (NorplantĀ®), or double barrier method (diaphragm plus condom). |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Indiana University Cancer Center | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University School of Medicine | Genzyme, a Sanofi Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the maximum tolerated dose (MTD) of clofarabine in association with high-dose etoposide and cyclophosphamide followed by ASCT in patients with refractory lymphoma malignancies. | 1 yr | Yes | |
Secondary | Assessment of the toxicity of the combination of clofarabine, and high-dose etoposide and cyclophosphamide-- Describe engraftment kinetics-- Describe the response rate-- Describe relapse rate and event-free survival-- Assess clofarabine p | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06014073 -
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
Terminated |
NCT00909948 -
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
Recruiting |
NCT05370547 -
Chidamide Bridging for CAR-T Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06285422 -
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
|
Phase 1 | |
Withdrawn |
NCT01101581 -
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
|
Phase 1/Phase 2 | |
Terminated |
NCT00038818 -
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT01789723 -
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
|
Phase 1 | |
Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 | |
Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
Terminated |
NCT00714259 -
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
|
Phase 2/Phase 3 | |
Completed |
NCT01018758 -
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
|
Phase 2 | |
Completed |
NCT00001830 -
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
|
Phase 1 | |
Recruiting |
NCT01063439 -
BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)
|
Phase 2 | |
Completed |
NCT01527422 -
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
|
Phase 1/Phase 2 | |
Completed |
NCT00834951 -
Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04497688 -
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
|
N/A | |
Completed |
NCT00597714 -
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT00001430 -
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
|
Phase 2 |